section name header

Pronunciation ⬇

dye-peer-ID-a-mole

Classifications ⬆ ⬇

Therapeutic Classification: antiplatelet agents, diagnostic agents (coronary vasodilators)

Pharmacologic Classification: platelet adhesion inhibitors

Indications ⬆ ⬇

BEERS REMS


Action ⬆ ⬇

  • PO: Decreases platelet aggregation by inhibiting the enzyme phosphodiesterase.
  • IV: Produces coronary vasodilation by inhibiting adenosine uptake.
Therapeutic effects:
  • PO: Inhibition of platelet aggregation and subsequent thromboembolic events.
  • IV: In diagnostic thallium imaging, dipyridamole dilates normal coronary arteries, reducing flow to vessels that are narrowed and causing abnormal thallium distribution.

Pharmacokinetics ⬆ ⬇

Absorption: Moderately absorbed (30–60%) after oral administration. IV administration results in complete bioavailability.

Distribution: Widely distributed to tissues.

Metabolism/Excretion: Metabolized by the liver; excreted in the bile.

Half-Life: 10 hr.

Time/Action Profile ⬆ ⬇

(PO = antiplatelet activity, IV = coronary vasodilation)

ROUTEONSETPEAKDURATION
POunknownunknownunknown
IVunknown6.5 min‡30 min

‡From start of infusion.



Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

CV: hypotension, arrhythmias, flushing, IV onlyMI

GI: nausea, diarrhea, GI upset, vomiting

Derm: rash

Neuro: dizziness, headache, syncope, IV onlytransient cerebral ischemia, weakness

Resp: IV onlybronchospasm

Interactions ⬆ ⬇

Drug-drug:

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

(Generic available)

Assessment ⬆ ⬇

Lab Test Considerations:

Implementation ⬆ ⬇

IV Administration:

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆ ⬇

Persantine

Canadian Brand Names ⬆

Persantine